Sector News

Amgen appoints senior VP and head of the European region

June 16, 2015
Life sciences
Amgen has named Corinne Le Goff as senior vice president and head of the European region.
 
Effective from June 1, Le Goff will be responsible for leading Amgen’s growth in Europe and will report directly to executive VP of global commercial operations, Anthony Hooper.
 
Commenting on her appointment, Le Goff said: “This is a pivotal moment for Amgen with a number of innovative new compounds either in the late stage clinical research or under review by the European regulatory authorities. 
 
“I am delighted to have the opportunity to lead the team in Europe at this exciting time.”
 
Le Goff joins from Roche, where she most recently served as president since 2012. In the role, she successfully led the business and a team of over 1,200 staff and helped evolve the business into one with a greater focus on market access and key account management.
 
Previously, Le Goff spent five years in strategic commercial leadership roles managing therapeutic areas at Roche, where she was senior VP of global product strategy for the neurosciences franchise and at Merck Serono, where she was senior VP of strategy and global marketing for neurology, rheumatology and immunology.
 
Hooper added: “Corinne brings strong vision and leadership to our European operations based on her broad strategic and operational experience in large healthcare organisations at both the global and affiliate level. I am delighted to welcome her to the team”.
 
Source: Amgen

comments closed

Related News

March 24, 2024

Johnson Matthey to sell its Medical Devices business for $700 million

Life sciences

Johnson Matthey Plc (JM; London) announced that it has signed a definitive agreement to sell 100% of its Medical Device Components business (MDC) to Montagu Private Equity (Montagu) for cash consideration of US$700 million (£550 million) on a cash free debt free basis.

March 24, 2024

Lonza acquires biologics manufacturing plant in California from Roche

Life sciences

Lonza AG (Basel, Switzerland) announced it has signed an agreement to acquire the Genentech large-scale biologics manufacturing site in Vacaville, Calif. from Roche (Basel, Switzerland) for $1.2 billion. The acquisition will significantly increase Lonza’s large-scale biologics manufacturing capacity.

March 24, 2024

Roquette to acquire IFF Pharma Solutions to boost global excipient presence

Life sciences

Roquette plans to acquire International Flavors & Fragrances (IFF) Pharma Solutions for an enterprise value of up to €2.85 billion (US$3.09 billion). With the acquisition set to close in the first half of 2025, the plant-based ingredient and pharmaceutical excipients supplier aims to reinforce its position in the pharmaceutical industry.

How can we help you?

We're easy to reach